Patents by Inventor Andrea Van Elsas

Andrea Van Elsas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
    Patent number: 11959924
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: April 16, 2024
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • Chimeric alkaline phosphatase-like proteins
    Patent number: 11746340
    Abstract: The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: September 5, 2023
    Assignee: AM-PHARMA B.V.
    Inventors: Willem Raaben, Luigi Johannes Cornelius Jonk, Erik Jan Van Den Berg, Andrea Van Elsas, José Luis Millán
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220135677
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: SAIROPA B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220135671
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 5, 2022
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
  • METHODS FOR PERFORMING EX VIVO DIAGNOSTIC TESTS FOR THE PRESENCE OF A PROLIFERATION-INDUCING LIGAND (APRIL) IN A HUMAN SAMPLE
    Publication number: 20210325404
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Application
    Filed: June 28, 2021
    Publication date: October 21, 2021
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • ALTERED APRIL BINDING ANTIBODIES
    Publication number: 20210221900
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
    Patent number: 11047864
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 29, 2021
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • CHIMERIC ALKALINE PHOSPHATASE-LIKE PROTEINS
    Publication number: 20210163905
    Abstract: The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 3, 2021
    Inventors: Willem RAABEN, Luigi Johannes Cornelius Jonk, Erik Jan Van Den Berg, Andrea Van Elsas, José Luis MILLÁN
  • Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)
    Patent number: 10961316
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: March 30, 2021
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • Anti-SIRP? antibodies
    Patent number: 10851164
    Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: December 1, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Erik Voets, Paul Vink, David Lutje Hulsik
  • Chimeric alkaline phosphatase-like proteins
    Patent number: 10822597
    Abstract: The invention relates to improved alkaline phosphatases, pharmaceutical compositions comprising improved alkaline phosphatases and the use of improved alkaline phosphatases for preventing, treating or curing diseases.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: November 3, 2020
    Assignee: AM-Pharma B.V.
    Inventors: Willem Raaben, Luigi Johannes Cornelius Jonk, Erik Jan Van Den Berg, Andrea Van Elsas, José Luis Millán
  • Anti-HCTLA-4 antibodies
    Patent number: 10808030
    Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: October 20, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • ALTERED APRIL BINDING ANTIBODIES
    Publication number: 20200079859
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Application
    Filed: August 12, 2019
    Publication date: March 12, 2020
    Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
  • Downstream Processing of an Alkaline Phosphatase
    Publication number: 20200063112
    Abstract: The invention relates to the field of downstream processing (DSP) of an alkaline phosphatase (AP). More specifically, it relates to a method for reducing host cell protein content in a composition comprising AP. The invention further relates to a composition comprising an AP and a reduced content of a host cell protein.
    Type: Application
    Filed: September 4, 2019
    Publication date: February 27, 2020
    Applicant: AM-Pharma B.V.
    Inventors: Luigi Johannes Cornelius JONK, Stephen Edward CONNOR, Erik Jan VAN-DEN BERG, Andrea VAN ELSAS, Abhinav Alok SHUKLA, Heather Bethea HORNE, Susan COOK, Timothy Martin KELLY, Victoria Anne DOWLING, Mialy Fanjamalala RAMAROSON
  • Downstream processing of an alkaline phosphatase
    Patent number: 10570380
    Abstract: The invention relates to the field of downstream processing (DSP) of an alkaline phosphatase (AP). More specifically, it relates to a method for reducing host cell protein content in a composition comprising AP. The invention further relates to a composition comprising an AP and a reduced content of a host cell protein.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 25, 2020
    Assignee: AM-PHARMA B.V.
    Inventors: Luigi Johannes Cornelius Jonk, Stephen Edward Connor, Erik Jan Van Den Berg, Andrea Van Elsas, Abhinav Alok Shukla, Heather Bethea Horne, Susan Cook, Timothy Martin Kelly, Victoria Anne Dowling, Mialy Fanjamalala Ramaroson
  • Anti-CD27 antibodies
    Patent number: 10556957
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 11, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Anti-PD-1 antibodies
    Patent number: 10494436
    Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 3, 2019
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
  • ANTI-CD27 ANTIBODIES
    Publication number: 20190300618
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: October 3, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Method of treating IgA nephropathy by administering humanized APRIL-binding antibodies
    Patent number: 10377830
    Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 13, 2019
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema